U-46619

U-46619 is a stable synthetic analog of Thromboxane A2 (TXA2), which was first described in the literature in 1975 by scientists at the Upjohn Company. It is commonly used in laboratory research to induce platelet aggregation and blood vessel constriction.

Chemistry[edit | edit source]

U-46619 is a member of the prostanoid class of compounds, and its chemical structure is similar to that of the naturally occurring eicosanoid, thromboxane A2. The compound is a stable analog, meaning it does not readily degrade in the body, making it useful for laboratory studies.

Pharmacology[edit | edit source]

U-46619 mimics the action of thromboxane A2, a potent vasoconstrictor and platelet aggregator. It acts by binding to the thromboxane receptor, TP, which is found on the surface of platelets and vascular smooth muscle cells. This binding triggers a series of events leading to platelet aggregation and vasoconstriction.

Uses in Research[edit | edit source]

U-46619 is widely used in research to study the role of thromboxane A2 in various physiological and pathological processes. It is often used to induce platelet aggregation in vitro, and to cause vasoconstriction in isolated blood vessel preparations. It has also been used to study the effects of various drugs on platelet function and blood vessel tone.

Safety[edit | edit source]

As a potent vasoconstrictor, U-46619 can cause significant increases in blood pressure if administered systemically. Therefore, it should be used with caution in laboratory animals, and appropriate measures should be taken to monitor and control blood pressure.

See Also[edit | edit source]

U-46619 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.